comprehensive -WSS

comprehensive

author：fashion 2025-09-28 21:57:16 - browse：83244

Novo Nordisk Denmark — LISELOTTE SABROE/AFP/Getty Images

An oral version of semaglutide, the drug marketed as Ozempic and Wegovy, led to dramatic weight loss in a trial enrolling people with obesity, manufacturer Novo Nordisk said Monday, data that could bolster what is already a blockbuster medicine.

In the study, which enrolled nearly 700 adults classified as having overweight or obesity, patients treated with a daily semaglutide tablet lost 15.1% of their body weight over the course of 17 months, while those on placebo lost 2.4%, Novo Nordisk said. The result is comparable to weekly injections of Wegovy, which in an earlier study led to 14.9% weight loss over the same period of time. In both studies, the most common side effects were gastrointestinal distress, with the majority of cases graded mild or moderate, the company said.

Novo Nordisk said it plans to submit oral semaglutide for U.S. and E.U. approvals later this year. A lower-dose version of the drug is already approved as a treatment for type 2 diabetes under the brand name Rybelsus.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Biotech reporter’s notebook: A sunnier mood at JPM 2024

hotspot

WSS

Iran moves toward freeing 5 American citizens who had been imprisoned, in rare deal

Maui funeral service workers on devastation of fires: 'I'm in shock'

DeSantis can now import cheaper drugs. But will Biden get credit?

After John Oliver segment, STAT readers share their opioid

DeSantis can now import cheaper drugs. But will Biden get credit?

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

entertainment

comprehensive

focus

How one medical school became remarkably diverse

Target recalls 2.2 million additional candles due to laceration, burn hazards

In age of alternative facts, a scholarly course on calling out crap

FDA’s Peter Marks seems inclined to back Sarepta’s gene therapy

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Heart disease and mental health: A look at cardiac psychology

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: 2023 in review, and a look at biotech in 2024

Virginia high school admissions case could be legal follow

Fauci’s Covid grilling leads GOP to weigh foreign research rules

explore

Readout LOUD podcast: FTC v. biotech, future of Pfizer and Vertex

The SUPPORT Act is critical to fighting the opioid crisis

Three issues to watch in global health in 2024

Kim Kardashian sparks debate on benefits of full

House GOP releases memo on Hunter Biden foreign business dealings, reviving old claims

Pharma budget tightening trickles down to Doximity

focus

knowledge

hotspot

hotspot